SecSonar.com

TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

TScan Therapeutics, Inc. (TCRX) is a Biotechnology company based in US with a market capitalization of $67.2M. Revenue grew 266.6% year-over-year and free cash flow was negative at -$139.7M. This page tracks TCRX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 200 employees · IPO Jul 16, 2021

Valuation

Valuation & price

$1.00 · as of May 17, 2026 · -60.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

0.55

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$2.48$1.67$0.87Jul 25Dec 25Jul 26Jul 7, 25$1.45Jul 9, 25$1.84Jul 11, 25$1.81Jul 15, 25$1.77Jul 17, 25$1.89Jul 21, 25$1.83Jul 23, 25$1.86Jul 25, 25$1.93Jul 29, 25$1.80Jul 31, 25$1.74Aug 4, 25$1.71Aug 6, 25$1.73Aug 11, 25$1.61Aug 13, 25$1.77Aug 15, 25$1.80Aug 19, 25$1.68Aug 21, 25$1.74Aug 25, 25$1.90Aug 27, 25$1.87Aug 29, 25$1.80Sep 3, 25$1.87Sep 5, 25$1.91Sep 9, 25$1.84Sep 11, 25$1.85Sep 16, 25$1.72Sep 18, 25$1.72Sep 22, 25$1.78Sep 24, 25$1.84Sep 26, 25$1.85Sep 30, 25$1.82Oct 2, 25$2.18Oct 6, 25$2.05Oct 8, 25$1.98Oct 10, 25$2.21Oct 14, 25$2.11Oct 16, 25$2.48Oct 21, 25$2.34Oct 23, 25$2.29Oct 27, 25$2.28Oct 29, 25$1.92Oct 31, 25$1.94Nov 4, 25$1.12Nov 6, 25$1.16Nov 10, 25$1.09Nov 12, 25$1.19Nov 14, 25$1.10Nov 18, 25$0.99Nov 20, 25$0.99Nov 25, 25$0.98Nov 28, 25$1.11Dec 2, 25$0.95Dec 4, 25$1.09Dec 8, 25$1.00Dec 10, 25$1.03Dec 12, 25$1.01Dec 16, 25$0.95Dec 18, 25$0.93Dec 22, 25$0.90Dec 24, 25$1.04Dec 29, 25$1.03Jan 2, 26$1.02Jan 6, 26$1.14Jan 8, 26$1.18Jan 12, 26$1.17Jan 14, 26$1.20Jan 16, 26$1.13Jan 21, 26$1.14Jan 23, 26$1.14Jan 27, 26$1.12Jan 29, 26$1.04Feb 2, 26$1.02Feb 4, 26$0.96Feb 9, 26$0.98Feb 11, 26$0.97Feb 13, 26$0.93Feb 18, 26$1.02Feb 20, 26$1.01Feb 24, 26$1.05Feb 26, 26$1.11Mar 2, 26$1.05Mar 4, 26$1.08Mar 6, 26$1.12Mar 10, 26$1.18Mar 12, 26$1.13Mar 17, 26$1.09Mar 19, 26$1.04Mar 23, 26$1.04Mar 25, 26$1.04Mar 27, 26$0.99Mar 31, 26$1.01Apr 2, 26$1.01Apr 7, 26$1.07Apr 9, 26$1.06Apr 13, 26$1.02Apr 15, 26$1.07Apr 17, 26$1.19Apr 22, 26$1.25Apr 24, 26$1.26Apr 28, 26$1.26Apr 30, 26$1.16May 4, 26$1.22May 6, 26$1.25May 8, 26$1.26May 12, 26$1.15May 14, 26$1.11May 18, 26$1.00May 20, 26$0.99May 22, 26$1.06May 28, 26$1.08Jun 1, 26$1.01Jun 3, 26$0.97Jun 5, 26$0.98Jun 9, 26$0.97Jun 11, 26$0.92Jun 15, 26$0.95Jun 17, 26$0.90Jun 22, 26$0.87Jun 24, 26$0.88Jun 26, 26$0.97Jul 2, 26$1.06
$0.8452-week range$2.52
Loading valuation history…

Fundamentals

Key fundamentals

$67.2M

Market cap

266.6%

Revenue growth (YoY)

72.2%

Gross margin

-$139.7M

Free cash flow (USD)

-$58.3M

Net debt

Net cash position

16.0%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2019 → 2025

FY 2019$0.00FY 2020$1.1MFY 2021$10.1MFY 2022$13.5MFY 2023$21.0MFY 2024$2.8MFY 2025$10.3M
$0$10.3M

Free cash flow by year

2019 → 2025

FY 2019$-13.8MFY 2020$-7.3MFY 2021$-58.6MFY 2022$-70.7MFY 2023$-64.5MFY 2024$-114.6MFY 2025$-139.7M
-$13.8M-$139.7M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202572.2%
100.0%72.2%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventClinical Trial UpdateJun 22, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 22, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing
  • 8-K eventVice President ResignationApr 2, 2026Filing

Questions

Frequently asked questions

What is TScan Therapeutics, Inc.'s market cap?

TScan Therapeutics, Inc. (TCRX) has a market capitalization of $67.2M.

What is TCRX's P/E ratio?

A meaningful P/E ratio is not available for TCRX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is TCRX's price-to-book (P/B) ratio?

TCRX trades at 0.55 times book value per share.

Are insiders buying TCRX stock?

SEC Form 4 filings show no open-market insider buys at TScan Therapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

CLNN

Clene Inc.

$67.7M

CBUS

Cibus, Inc.

$66.6M

SPRB

Spruce Biosciences, Inc.

$68.2M

MNOV

MediciNova, Inc.

$66M

IMA

ImageneBio Inc

$65.9M

IMMP

Immutep Limited

$65M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.